Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch
Executive Summary
"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.
You may also be interested in...
Fewer Drug Launches In 2022, But Standouts Among Them
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.
ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Novartis builds radioligand therapy franchise; BMS pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.